Article Abstract

Moderate hypofractionation for prostate cancer

Authors: W. Robert Lee, Bridget F. Koontz

Abstract

The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens could maintain the therapeutic ratio with logistic and nancial advantages. In the last two decades medical evidence, weak and strong, has accumulated on the ef cacy and toxicity of hypofractionated regimens in the radiotherapeutic treatment of prostate cancer. This brief review will focus on the results of randomized trials that compare moderate hypofractionation (HF) to conventional fractionation (CF). Extreme HF is covered in a separate review within this issue.

Refbacks

  • There are currently no refbacks.

Article Options

Download Citation